File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Regression of left ventricular hypertrophy after treatment of hypertension: Comparison of directed M-echocardiography with magnetic resonance imaging in quantification of serial mass changes
  • Basic View
  • Metadata View
  • XML View
TitleRegression of left ventricular hypertrophy after treatment of hypertension: Comparison of directed M-echocardiography with magnetic resonance imaging in quantification of serial mass changes
 
AuthorsTse, HF1
Cheung, BMY1
Ng, W1
Chan, JKF2
Devereux, RB3
Lau, CP1
 
KeywordsChemicals And Cas Registry Numbers
 
Issue Date2003
 
PublisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/cardfail
 
CitationJournal Of Cardiac Failure, 2003, v. 9 n. 2, p. 122-127 [How to Cite?]
DOI: http://dx.doi.org/10.1054/jcaf.2003.12
 
AbstractBackground: This study sought to validate the reliability of serial echocardiographic measurements in detecting left ventricular (LV) hypertrophy regression by using magnetic resonance imaging (MRI) as a reference standard. Methods and Results: We studied a small population (n = 20) of patients enrolled in the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial for evaluating LV hypertrophy regression. LV mass was measured by both echocardiography and MRI at baseline and after 1 year. As compared with baseline, systolic and diastolic blood pressures were significantly decreased after 1 year (all P < .05). Echocardiographic technique showed an overestimation of LV mass by 27.6 g at baseline (P = .005) and by 37.1 g after 1 year (P < .001), and there were wide 95% limits of agreement (±36.0 g at baseline; and ±27.6 g after 1 year) when compared with MRI measurement. Significant changes of LV mass from baseline of -20 ± 22 g (P < .01) and -29 ± 19 g (P < .01) were detected by using echocardiography and MRI after 1 year, respectively (P = .02), and there were similarly wide limits of agreement for change in LV mass (±24.2 g). Conclusions: Despite the use of careful methodology, echocardiographic measurement of LV mass at a single time point or for serial studies resulted in significant variation in LV mass estimates from measurement using MRI.
 
ISSN1071-9164
2013 Impact Factor: 3.065
 
DOIhttp://dx.doi.org/10.1054/jcaf.2003.12
 
ISI Accession Number IDWOS:000182332900008
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorTse, HF
 
dc.contributor.authorCheung, BMY
 
dc.contributor.authorNg, W
 
dc.contributor.authorChan, JKF
 
dc.contributor.authorDevereux, RB
 
dc.contributor.authorLau, CP
 
dc.date.accessioned2010-09-17T10:20:56Z
 
dc.date.available2010-09-17T10:20:56Z
 
dc.date.issued2003
 
dc.description.abstractBackground: This study sought to validate the reliability of serial echocardiographic measurements in detecting left ventricular (LV) hypertrophy regression by using magnetic resonance imaging (MRI) as a reference standard. Methods and Results: We studied a small population (n = 20) of patients enrolled in the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial for evaluating LV hypertrophy regression. LV mass was measured by both echocardiography and MRI at baseline and after 1 year. As compared with baseline, systolic and diastolic blood pressures were significantly decreased after 1 year (all P < .05). Echocardiographic technique showed an overestimation of LV mass by 27.6 g at baseline (P = .005) and by 37.1 g after 1 year (P < .001), and there were wide 95% limits of agreement (±36.0 g at baseline; and ±27.6 g after 1 year) when compared with MRI measurement. Significant changes of LV mass from baseline of -20 ± 22 g (P < .01) and -29 ± 19 g (P < .01) were detected by using echocardiography and MRI after 1 year, respectively (P = .02), and there were similarly wide limits of agreement for change in LV mass (±24.2 g). Conclusions: Despite the use of careful methodology, echocardiographic measurement of LV mass at a single time point or for serial studies resulted in significant variation in LV mass estimates from measurement using MRI.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Cardiac Failure, 2003, v. 9 n. 2, p. 122-127 [How to Cite?]
DOI: http://dx.doi.org/10.1054/jcaf.2003.12
 
dc.identifier.doihttp://dx.doi.org/10.1054/jcaf.2003.12
 
dc.identifier.epage127
 
dc.identifier.hkuros99478
 
dc.identifier.isiWOS:000182332900008
 
dc.identifier.issn1071-9164
2013 Impact Factor: 3.065
 
dc.identifier.issue2
 
dc.identifier.pmid12751133
 
dc.identifier.scopuseid_2-s2.0-0037388920
 
dc.identifier.spage122
 
dc.identifier.urihttp://hdl.handle.net/10722/91532
 
dc.identifier.volume9
 
dc.languageeng
 
dc.publisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/cardfail
 
dc.publisher.placeUnited States
 
dc.relation.ispartofJournal of Cardiac Failure
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAged
 
dc.subject.meshAntihypertensive Agents - therapeutic use
 
dc.subject.meshCalcium Channel Blockers - therapeutic use
 
dc.subject.meshEchocardiography
 
dc.subject.meshEnalapril - therapeutic use
 
dc.subject.meshFemale
 
dc.subject.meshHumans
 
dc.subject.meshHypertension - drug therapy
 
dc.subject.meshHypertrophy, Left Ventricular - diagnosis - prevention & control - ultrasonography
 
dc.subject.meshMagnetic Resonance Imaging
 
dc.subject.meshMale
 
dc.subject.meshNifedipine - therapeutic use
 
dc.subjectChemicals And Cas Registry Numbers
 
dc.titleRegression of left ventricular hypertrophy after treatment of hypertension: Comparison of directed M-echocardiography with magnetic resonance imaging in quantification of serial mass changes
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Tse, HF</contributor.author>
<contributor.author>Cheung, BMY</contributor.author>
<contributor.author>Ng, W</contributor.author>
<contributor.author>Chan, JKF</contributor.author>
<contributor.author>Devereux, RB</contributor.author>
<contributor.author>Lau, CP</contributor.author>
<date.accessioned>2010-09-17T10:20:56Z</date.accessioned>
<date.available>2010-09-17T10:20:56Z</date.available>
<date.issued>2003</date.issued>
<identifier.citation>Journal Of Cardiac Failure, 2003, v. 9 n. 2, p. 122-127</identifier.citation>
<identifier.issn>1071-9164</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/91532</identifier.uri>
<description.abstract>Background: This study sought to validate the reliability of serial echocardiographic measurements in detecting left ventricular (LV) hypertrophy regression by using magnetic resonance imaging (MRI) as a reference standard. Methods and Results: We studied a small population (n = 20) of patients enrolled in the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial for evaluating LV hypertrophy regression. LV mass was measured by both echocardiography and MRI at baseline and after 1 year. As compared with baseline, systolic and diastolic blood pressures were significantly decreased after 1 year (all P &lt; .05). Echocardiographic technique showed an overestimation of LV mass by 27.6 g at baseline (P = .005) and by 37.1 g after 1 year (P &lt; .001), and there were wide 95% limits of agreement (&#177;36.0 g at baseline; and &#177;27.6 g after 1 year) when compared with MRI measurement. Significant changes of LV mass from baseline of -20 &#177; 22 g (P &lt; .01) and -29 &#177; 19 g (P &lt; .01) were detected by using echocardiography and MRI after 1 year, respectively (P = .02), and there were similarly wide limits of agreement for change in LV mass (&#177;24.2 g). Conclusions: Despite the use of careful methodology, echocardiographic measurement of LV mass at a single time point or for serial studies resulted in significant variation in LV mass estimates from measurement using MRI.</description.abstract>
<language>eng</language>
<publisher>Churchill Livingstone. The Journal&apos;s web site is located at http://www.elsevier.com/locate/cardfail</publisher>
<relation.ispartof>Journal of Cardiac Failure</relation.ispartof>
<subject>Chemicals And Cas Registry Numbers</subject>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Antihypertensive Agents - therapeutic use</subject.mesh>
<subject.mesh>Calcium Channel Blockers - therapeutic use</subject.mesh>
<subject.mesh>Echocardiography</subject.mesh>
<subject.mesh>Enalapril - therapeutic use</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Hypertension - drug therapy</subject.mesh>
<subject.mesh>Hypertrophy, Left Ventricular - diagnosis - prevention &amp; control - ultrasonography</subject.mesh>
<subject.mesh>Magnetic Resonance Imaging</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Nifedipine - therapeutic use</subject.mesh>
<title>Regression of left ventricular hypertrophy after treatment of hypertension: Comparison of directed M-echocardiography with magnetic resonance imaging in quantification of serial mass changes</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1054/jcaf.2003.12</identifier.doi>
<identifier.pmid>12751133</identifier.pmid>
<identifier.scopus>eid_2-s2.0-0037388920</identifier.scopus>
<identifier.hkuros>99478</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-0037388920&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>9</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>122</identifier.spage>
<identifier.epage>127</identifier.epage>
<identifier.isi>WOS:000182332900008</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Queen Mary Hospital Hong Kong
  3. Weill Cornell Medical Center